Using epigenetic therapy to treat lung fibrosis
Official title: Targeting Lung Fibrosis Using Epigenetic Therapy
Funded at University of Kentucky · NIH-10990721 · Data updated 2026-11-12
This study is looking at how a drug called tazemetostat might help improve lung health for people with pulmonary fibrosis by changing the activity of a specific enzyme, and it will use both human and animal cells to see how it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $698,070 |
| NIH project number | 1R01HL170193-01A1 |
| Project ID | NIH-10990721 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary fibrosis who may not have responded adequately to existing therapies.
✕Less likely to help
Patients with early-stage pulmonary fibrosis or those whose condition is stable may not see significant benefits from this research.
What this research studies
This research investigates how modifying the activity of a specific enzyme, EZH2, can potentially reverse or prevent the progression of pulmonary fibrosis, a disease characterized by the buildup of scar tissue in the lungs. The study will utilize both human and mouse cell cultures, as well as established animal models, to explore the effects of an FDA-approved drug, tazemetostat, on lung cells. By examining how this drug influences cellular behavior and signaling pathways, the research aims to identify new therapeutic strategies for patients suffering from this debilitating condition.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments that not only extend life but also improve lung function and quality of life for patients with pulmonary fibrosis.
How similar studies have gone: Previous research has shown promise in targeting epigenetic mechanisms for various diseases, suggesting that this approach may yield beneficial results for pulmonary fibrosis as well.
Where this research is happening
-
University of Kentucky
Lexington, United States Active
Researchers
- Principal investigator: Brainson, Christine Fillmore — University of Kentucky
- Study coordinator: Brainson, Christine Fillmore
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.